Details of Disease

General Information of Disease (ID: DISYV7YJ)

• Disease Name: Ischemic stroke
• Synonyms: childhood arterial ischemic stroke; childhood AIS; paediatric AIS; childhood arterial ischaemic stroke; pediatric AIS
• Disease Class: 8B11: Cerebral ischaemic stroke
• Disease Hierarchy:
  DIS9Q4RT: Brain ischaemia
  DISLG4XS: Arterial disorder
  DISX6UHX: Stroke
  DIS5XOOY: Ischemia
  DISYV7YJ: Ischemic stroke
• ICD Code:
  ICD-11: ICD-11: 8B11.5Z
  ICD-9: ICD-9: 434.91
  Expand ICD-9: 434.91
• Disease Identifiers:
  MONDO ID: MONDO_0018585
  UMLS CUI: C5680049
  OMIM ID: 601367
  MedGen ID: 1803840
  HPO ID: HP:0002140
  Orphanet ID: 439175
  SNOMED CT ID: 1197363004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Levorphanol	DMGS80V	Approved	Small molecular drug	[1]
Magnesium	DMU4ORS	Approved	Small molecular drug	[2]
Vinpocetine	DMVN2E6	Approved	Small molecular drug	[3]

This Disease is Treated as An Indication in 24 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Asundexian	DMLZMU2	Phase 3	Small molecule	[4]
Desmoteplase	DMDLU4Z	Phase 3	NA	[5]
MultiStem	DMOT705	Phase 3	NA	[6]
3K3A-APC	DMTLR6Y	Phase 2	NA	[7]
BMS-986177	DM4QHZS	Phase 2	Small molecular drug	[8]
CP-101,606	DMIU19E	Phase 2	Small molecular drug	[9]
DM199	DM0157T	Phase 2	Recombinant protein	[7]
GM-602	DM8R4YU	Phase 2	NA	[10]
GM602	DMNCVQT	Phase 2	NA	[11]
Mesenchymal stem cell therapy	DMW7QYT	Phase 2	NA	[10]
SB-623	DM4NY58	Phase 2	Small molecular drug	[7]
SB623	DMCXTM0	Phase 2	Cell therapy	[12]
SCH-900271	DMBJY1Z	Phase 2	Small molecular drug	[13]
Senktide	DMOH8LD	Phase 2	Small molecular drug	[10]
TF0023	DMF61ML	Phase 2	NA	[7]
V10153	DMO6JD4	Phase 2	NA	[14]
NCS-01	DM7KPMD	Phase 1/2	Cell therapy	[15]
NVX-208	DMRT89S	Phase 1/2	NA	[7]
CNT0-0007	DMPKW3A	Phase 1	NA	[16]
DS-1040	DMXCN37	Phase 1	NA	[17]
DTRI-031	DM0BCT7	Phase 1	NA	[18]
LT-3001	DM42MWU	Phase 1	NA	[7]
MP-124	DMQRNTG	Phase 1	NA	[19]
PP-007	DMZS5RN	Phase 1	Peptide	[20]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PF-3049423	DMTSED5	Discontinued in Phase 2	NA	[21]

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cx-602	DME462X	Preclinical	NA	[22]
Cx-603	DM8IMML	Preclinical	NA	[22]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aptiganel HCl	DMF1264	Investigative	Small molecular drug	[23]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009336)
• [2] Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5285).
• [4] ClinicalTrials.gov (NCT05686070) A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA. U.S.National Institutes of Health.
• [5] ClinicalTrials.gov (NCT00111852) Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2). U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT03545607) MultiStem Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2). U.S. National Institutes of Health.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] ClinicalTrials.gov (NCT03766581) A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel (AXIOMATIC-SSP). U.S. National Institutes of Health.
• [9] Current status of neuroprotective agents in the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2001 Jan;1(1):13-8.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] ClinicalTrials.gov (NCT01221246) Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours (GMAIS). U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT02448641) Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke (ACTIsSIMA). U.S. National Institutes of Health.
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8469).
• [14] ClinicalTrials.gov (NCT00144014) Safety and Efficacy Study in Acute Ischaemic Stroke. U.S. National Institutes of Health.
• [15] ClinicalTrials.gov (NCT03915431) A Phase 1/2 Randomized Study to Evaluate the Safety and Tolerability of Intracarotid Artery Administration of NCS-01 in Patients With Acute Ischemic Stroke. U.S.National Institutes of Health.
• [16] ClinicalTrials.gov (NCT01273467) A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Knownas Stroke). U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT02071004) DS1040b/Aspirin Drug/Drug Interaction Study. U.S. National Institutes of Health.
• [18] ClinicalTrials.gov (NCT05005520) A Randomized, Double-Blind, Single-Center, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of Intravenous DTRI-031 in Healthy Volunteers. U.S.National Institutes of Health.
• [19] MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model. Brain Res. 2011 Sep 2;1410:122-31.
• [20] ClinicalTrials.gov (NCT04677777) A Randomized, Phase 1, Contemporaneously Controlled, Multicenter Study to Assess the Safety of PP-007 in Subjects With Acute Ischemic Stroke. U.S.National Institutes of Health.
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031556)
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027323)
• [23] Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.